Update (June 17, 2026): Lymph Food RCT Improves Lesion Scores and Reduces Medication Use in Dogs with Atopic Dermatitis

TL;DR

A 112-day double-blinded RCT found that a complementary lymph food supplement (whey protein, vitamins, minerals, antioxidants) added to standard care significantly improved both lesion and pruritus scores in dogs with atopic dermatitis.

What just dropped

• Frizzo-Ramos et al. 2025 (Front Vet Sci, published Dec 19 2025, DOI 10.3389/fvets.2025.1657869; PMID 41487474; open access): 38 dogs with canine atopic dermatitis (cAD) in a 112-day, double-blinded, randomised study.
• Active group (n=19) received 10 g/day of a lymph food formulated with whey protein, vitamins, minerals, and antioxidants designed to bypass mucosal malabsorption barriers; control group (n=19) received hydrolysed food placebo. Concomitant medication use (JAK inhibitors, corticosteroids, antihistamines, cyclosporine, lokivetmab) was recorded.
• Active group showed significantly greater reductions in CADESI-4 scores (-55% vs +26% in placebo; p<0.0003) and Pruritus Visual Analog Scale scores (-1.8 vs -0.05; p=0.0074).
• Medication use significantly declined in the active group.
• A threefold greater proportion of dogs in the active group achieved treatment success (defined as at least 2-point PVAS decrease and at least 50% CADESI-4 reduction) compared with placebo.
• Red blood cell counts, packed cell volume, and serum iron increased in the active group but not in the placebo group.

Context

The study was conducted at the University of Veterinary Medicine Vienna and tested the hypothesis that micronutritional deficits -- specifically iron depletion and subclinical inflammation observed in cAD dogs despite meat-based diets -- drive mucosal malabsorption that can be bypassed by lymphatic nutrient delivery. The authors frame this as evidence of a causative role for nutritional deficiencies in skin inflammation, a mechanistic direction distinct from anti-cytokine or JAK inhibitor approaches.

Limitations: single centre; n=38; the lymph food product (ViaLym FlexCo) has a commercial affiliation with one author; long-term data beyond 112 days not yet available. Concomitant medication use was permitted and varied across animals, which adds confounding.

What this changes in oclacitinib-canine-atopic-dermatitis (https://www.thevoyage.ai/forvets/knowledge/oclacitinib-canine-atopic-dermatitis)

The Frizzo-Ramos 2025 RCT does not challenge the primary pharmacological evidence base for JAK inhibitors or anti-IL-31 antibodies but adds a novel adjunctive option. Dogs receiving JAK inhibitors, ciclosporin, or biologics with residual lesion burden may represent a candidate population for nutritional adjunct approaches. The significant decline in medication use in the active group supports the hypothesis that improving micronutritional status can modulate skin inflammation through a complementary pathway. Clinicians should be aware of the commercial authorship connection when appraising the evidence.

References

1. Frizzo-Ramos C, Doulidis PG, Burgener IA, et al. Lymph food to improve canine atopic dermatitis: a randomized, double-blinded, controlled trial in dogs with standard-care treatment. Front Vet Sci. 2025 Dec 19;12:1657869. DOI: 10.3389/fvets.2025.1657869 (https://doi.org/10.3389/fvets.2025.1657869)

Related reads

• Oclacitinib (Apoquel) for Canine Atopic Dermatitis: JAK Inhibition and Clinical Evidence
• Lokivetmab (Cytopoint) for Canine Atopic Dermatitis: IL-31 Targeting and Clinical Evidence
• Cyclosporine (Atopica) for Canine Atopic Dermatitis: Efficacy, Safety, and Clinical Place